First Time Loading...

BiVictriX Therapeutics PLC
LSE:BVX

Watchlist Manager
BiVictriX Therapeutics PLC Logo
BiVictriX Therapeutics PLC
LSE:BVX
Watchlist
Price: 11.5 GBX -4.17% Market Closed
Updated: May 8, 2024

BiVictriX Therapeutics PLC
Revenue

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

BiVictriX Therapeutics PLC
Revenue Peer Comparison

Comparables:
CNTA
AUTL
BCYC
IMCR
GNS

Competitive Revenue Analysis
Latest Figures & CAGR of Competitors

Company Revenue CAGR 3Y CAGR 5Y CAGR 10Y
BiVictriX Therapeutics PLC
LSE:BVX
Revenue
£0
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Centessa Pharmaceuticals PLC
NASDAQ:CNTA
Revenue
$6.9m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Autolus Therapeutics PLC
NASDAQ:AUTL
Revenue
$1.7m
CAGR 3-Years
0%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Bicycle Therapeutics PLC
NASDAQ:BCYC
Revenue
$41.6m
CAGR 3-Years
55%
CAGR 5-Years
31%
CAGR 10-Years
N/A
Immunocore Holdings PLC
NASDAQ:IMCR
Revenue
£249.4m
CAGR 3-Years
102%
CAGR 5-Years
60%
CAGR 10-Years
N/A
Genus PLC
LSE:GNS
Revenue
£673.1m
CAGR 3-Years
6%
CAGR 5-Years
7%
CAGR 10-Years
6%

See Also

What is BiVictriX Therapeutics PLC's Revenue?
Revenue
0 GBP

Based on the financial report for Dec 31, 2022, BiVictriX Therapeutics PLC's Revenue amounts to 0 GBP.